of Anaesthesiology

300 Pages·2013·5.45 MB·English

Volume 30 | e-Supplement 51 | June 2013
www.ejanaesthesiology.com
E
U
R
O
P
E
A
N
J
O
U
R
N
A
L
O
F
A
N
A
MAY 31 - JUNE 3 E
S
T
H
E
S
STOCKHOLM, SWEDEN IO
L
O
G
Y
European Journal
2014
of
V
o
Euroanaesthesia lum Anaesthesiology
e
3
0
e
-S
u
p
p
le
m
e
The European Anaesthesiology Congress n
t 5
1
Ju
n
e
2
0
1
3
Euroanaesthesia 2013
The European Anaesthesiology Congress
Abstracts Programme
Barcelona, Spain, June 1-4, 2013
Symposia
Refresher Courses
Workshops
Industrial Symposia & Exhibition
Abstract Presentations
CME Accreditation
EACCME - UEMS
Registration
P [phone]
F [phone]
E [email protected]
www.euroanaesthesia.org 5
1
2
0
Abstract submission from 65-
2
Friday 1 November to 0
N
Sunday 15 December 2013 SS
I
ESA omslag.indd 1

European Journal of Anaesthesiology
Volume 30 | e-Supplement 51 | June 2013
Abstracts and Programme
EUROANAESTHESIA 2013
The European Anaesthesiology Congress
1 - 4 June 2013
Barcelona, Spain
European Journal of Anaesthesiology
Editor-in-Chief Associate Editors Per H. Rosenberg Helsinki, Finland
Martin R. Tramèr Geneva, Switzerland Bernd W. Böttiger Cologne, Germany Charles-Marc Samama Paris, France
Malachy Columb Manchester, UK Francis Veyckemans Brussels, Belgium
Stefan G. De Hert Ghent, Belgium
Deputy Editors-in-Chief Pierre Diemunsch Strasbourg, France Methods, Statistics, Epidemiology
Walid Habre Geneva, Switzerland Argyro Fassoulaki Athens, Greece Nadia Elia Geneva, Switzerland
Bernhard Walder Geneva, Switzerland Thomas Fuchs-Buder Nancy, France
Peter Kranke Würzburg, Germany Journal Manager
Language Editors Patricia M. Lavand’homme Brussels, Belgium Bridget M. Benn Geneva, Switzerland
Alan Aitkenhead Nottingham, UK Doris Østergaard Copenhagen, Denmark
Gordon Lyons Leeds, UK Rolf Rossaint Aachen, Germany
Michael H. Nathanson Nottingham, UK
Matt Wiles, Sheffi eld, UK
European Journal of Anaesthesiology is the offi cial publication of Advertising enquiries The Point of Difference Ltd.,
the European Society of Anaesthesiology. The Journal publishes tel: [phone]; fax: [phone];
original scientifi c work. Preference is given to experimental work e-mail:[email protected]
or clinical observations in man, and to laboratory work of clinical
relevance. Special projects and reprints (U.S./Canada):
Alan Moore, email: [email protected]
Information for contributors
Special projects and reprints (non-U.S./Canada):
Papers should be submitted online at: www.editorialmanager.com/eja.
Silvia Serra, email: [email protected]
European Journal of Anaesthesiology (ISSN: 0265-0215) is pub-
Disclaimer
lished monthly by Lippincott Williams & Wilkins and distributed in the
The views expressed in this journal represent those of the authors
US by Mercury Airfreight International, Inc., 365 Blair Road, Avenel,
or advertisers only. In no way can they be construed necessarily to
NJ 07001. Periodicals postage paid at Rahway, NJ. POSTMASTER:
refl ect the view of either the Editors or the Publishers.
send address changes to European Journal of Anaesthesiology, PO
Box 1550, Hagerstown, MD 21741.
2013 Subscription rates
Individual $461 (USA); $461 (Rest of the World). Institutional $1,418
All correspondence should be addressed to the Editorial Offi ce:
(USA); $1,515 (Rest of the World). On-line only subscriptions for
European Journal of Anaesthesiology, Lippincott Williams & Wilkins,
Institutions are available through Ovid (www.ovid.com).
250 Waterloo Road, London, SE1 8RD, UK
Prices include handling and shipping, but not sales tax, e.g. VAT, GST,
Publisher Ian Burgess
MVG, MWS, AST and regional sales tax. Where applicable, please add
Editorial Coordinator Anna Rutkowska
sales tax to the listed prices at the appropriate rate. (The Canadian GST
Production Editor Duncan Martin-Holloway
of 7% will be added to the subscription price of all orders shipped to
Copyright © 2013 by European Society of Anaesthesiology. All Canada. Lippincott Williams & Wilkins’ GST Identifi cation Number is
right reserved. No part of this publication may be reproduced, 895524239.) Copies will be replaced without charge if the publisher
stored in a retrieval system, or transmitted in any form or by receives a request within 90 days of the mailing date, both in the USA
any means, electronic, mechanical, photocopying, recording and worldwide.
or otherwise without either the prior written permission of the
Subscription information
Publisher or a licence permitting restricted copying issued by the
European Journal of Anaesthesiology, Subscription
Copyright Licensing Authority and in the USA by the Copyright
Department, Lippincott Williams & Wilkins,
Clearance Center.
16522 Hunters Green Parkway, Hagerstown,
Printed on chlorine-free, recyclable paper from sustainable forests MD 21740-2116, USA, tel: + 1 301 223 2300; fax: + 1 301 223
meeting the requirements of ISO 9706, ISO 14001 and ISO 9001 2320. In the USA, call toll-free on 1 800 638 3030. In Japan, contact
in Singapore by COS Printers Pte Ltd. Typeset by Thomson Digital Wolters Kluwer Health Japan Co, Ltd, 1-28-36 Hongo, Bunkyo-ku,
Ltd., Noida Special Economic Zone, Noida, India. Tokyo 113, Japan, tel: + 81 3 3817 5675; fax: + 81 3 3815 6776.
E 2013
uroanaEsthEsia
Barcelona, Spain, 1 - 4 June 2013
The European Anaesthesiology Congress
ABSTRACT PRESENTATION PROGRAMME
Please note that all abstracts are presented as poster presentations: abstract presenters do not make a formal presentation
of their abstract in a separate room, using audiovisual aids (except for the Best Abstract Prize Competition and the Best
Abstracts - Runner-up Session 1 & 2). Instead, two chairpersons will conduct, in front of each poster, a short discussion of
each abstract with the presenter and the audience, for every abstract in that session. Poster presenters have been asked to
stand by their poster for 45 minutes before and 30 minutes after their session, to address further questions.
Date Time Reference Location Page
ESA Best Abstract Prize Competition (BAPC)
02.06.2013 14:00-15:30 ESAPC1 Room 120 1
Best Abstracts - Runner-up Sessions
02.06.2013 08:30-10:00 ESAAP1 Room 120 3
02.06.2013 10:30-12:00 ESAAP2 Room 120 5
Subcommittee 1 - Evidence-based Practice and Quality Improvement
01.06.2013 15:00-16:30 01AP1 Poster Area - ROW 1B 7
01.06.2013 15:00-16:30 01AP2 Poster Area - ROW 2B 10
03.06.2013 12:15-13:45 01AP3 Poster Area - ROW 1B 12
03.06.2013 14:00-15:30 01AP4 Poster Area - ROW 10A 15
03.06.2013 14:00-15:30 01AP5 Poster Area - ROW 11A 18
03.06.2013 16:00-17:30 01AP6 Poster Area - ROW 11B 21
03.06.2013 16:00-17:30 01AP7 Poster Area - ROW 12B 24
04.06.2013 08:30-10:00 01AP8 Poster Area - ROW 1A 28
Subcommittee 2 - Ambulatory Anaesthesia
02.06.2013 08:30-10:00 02AP1 Poster Area - ROW 1A 31
02.06.2013 10:30-12:00 02AP2 Poster Area - ROW 1B 34
Subcommittee 3 - Monitoring: Equipment and Computers
02.06.2013 14:00-15:30 03AP1 Poster Area - ROW 5B 37
02.06.2013 14:00-15:30 03AP2 Poster Area - ROW 6B 40
03.06.2013 10:30-12:00 03AP3 Poster Area - ROW 1A 43
03.06.2013 12:15-13:45 03AP4 Poster Area - ROW 2B 46
03.06.2013 14:00-15:30 03AP5 Poster Area - ROW 12A 48
04.06.2013 08:30-10:00 03AP6 Poster Area - ROW 2A 51
Subcommittee 4 - Clinical and Experimental Circulation
02.06.2013 10:30-12:00 04AP1 Poster Area - ROW 2B 54
02.06.2013 10:30-12:00 04AP2 Poster Area - ROW 3B 58
02.06.2013 16:00-17:30 04AP3 Poster Area - ROW 10B 61
02.06.2013 16:00-17:30 04AP4 Poster Area - ROW 11B 63
03.06.2013 10:30-12:00 04AP5 Poster Area - ROW 2A 67
03.06.2013 10:30-12:00 04AP6 Poster Area - ROW 3A 70
03.06.2013 12:15-13:45 04AP7 Poster Area - ROW 3B 73
03.06.2013 14:00-15:30 04AP8 Poster Area - ROW 13B 76
Date Time Reference Location Page
Subcommittee 5 - Respiration
03.06.2013 14:00-15:30 05AP1 Poster Area - ROW 14B 80
03.06.2013 14:00-15:30 05AP2 Poster Area - ROW 15B 83
04.06.2013 08:30-10:00 05AP3 Poster Area - ROW 3A 86
04.06.2013 08:30-10:00 05AP4 Poster Area - ROW 4A 89
Subcommittee 6 - Transfusion and Haemostasis
02.06.2013 14:00-15:30 06AP1 Poster Area - ROW 7B 92
02.06.2013 14:00-15:30 06AP2 Poster Area - ROW 15B 95
02.06.2013 16:00-17:30 06AP3 Poster Area - ROW 12B 98
Subcommittee 7 – Neurosciences
01.06.2013 15:00-16:30 07AP1 Poster Area - ROW 3B 101
01.06.2013 15:00-16:30 07AP2 Poster Area - ROW 4B 104
02.06.2013 16:00-17:30 07AP3 Poster Area - ROW 13A 107
02.06.2013 16:00-17:30 07AP4 Poster Area - ROW 14A 110
04.06.2013 08:30-10:00 07AP5 Poster Area - ROW 5B 112
Subcommittee 8 - Regional Anaesthesia
02.06.2013 10:30-12:00 08AP1 Poster Area - ROW 5A 116
02.06.2013 10:30-12:00 08AP2 Poster Area - ROW 6A 119
02.06.2013 14:00-15:30 08AP3 Poster Area - ROW 8B 122
02.06.2013 14:00-15:30 08AP4 Poster Area - ROW 9A 125
03.06.2013 10:30-12:00 08AP5 Poster Area - ROW 4A 128
03.06.2013 10:30-12:00 08AP6 Poster Area - ROW 5B 131
03.06.2013 12:15-13:45 08AP7 Poster Area - ROW 4B 134
03.06.2013 12:15-13:45 08AP8 Poster Area - ROW 5A 136
Subcommittee 9 – Pharmacology
01.06.2013 15:00-16:30 09AP1 Poster Area - ROW 5A 139
02.06.2013 08:30-10:00 09AP2 Poster Area - ROW 2A 142
02.06.2013 08:30-10:00 09AP3 Poster Area - ROW 3A 145
02.06.2013 16:00-17:30 09AP4 Poster Area - ROW 15A 148
02.06.2013 16:00-17:30 09AP5 Poster Area - ROW 16A 151
03.06.2013 10:30-12:00 09AP6 Poster Area - ROW 6B 154
Subcommittee 10 - Paediatric Anaesthesia and Intensive Care
02.06.2013 16:00-17:30 10AP1 Poster Area - ROW 17B 157
03.06.2013 14:00-15:30 10AP2 Poster Area - ROW 16B 159
04.06.2013 08:30-10:00 10AP3 Poster Area - ROW 6B 162
Subcommittee 11 - Obstetric Anaesthesia
01.06.2013 15:00-16:30 11AP1 Poster Area - ROW 6A 165
02.06.2013 16:00-17:30 11AP2 Poster Area - ROW 18B 168
02.06.2013 16:00-17:30 11AP3 Poster Area - ROW 19B 172
03.06.2013 14:00-15:30 11AP4 Poster Area - ROW 17A 175
03.06.2013 14:00-15:30 11AP5 Poster Area - ROW 18A 177
Date Time Reference Location Page
Subcommittee 12 - Intensive Care Medicine
02.06.2013 14:00-15:30 12AP1 Poster Area - ROW 10A 181
02.06.2013 14:00-15:30 12AP2 Poster Area - ROW 11A 184
02.06.2013 14:00-15:30 12AP3 Poster Area - ROW 12A 187
03.06.2013 12:15-13:45 12AP4 Poster Area - ROW 6A 190
03.06.2013 12:15-13:45 12AP5 Poster Area - ROW 7A 194
03.06.2013 12:15-13:45 12AP6 Poster Area - ROW 8A 197
Subcommittee 13 - Resuscitation and Emergency Medicine
02.06.2013 10:30-12:00 13AP1 Poster Area - ROW 7A 200
03.06.2013 10:30-12:00 13AP2 Poster Area - ROW 7B 202
Subcommittee 14 - Acute and Chronic Pain Management
01.06.2013 15:00-16:30 14AP1 Poster Area - ROW 7A 204
01.06.2013 15:00-16:30 14AP2 Poster Area - ROW 8A 207
02.06.2013 14:00-15:30 14AP3 Poster Area - ROW 13B 210
02.06.2013 14:00-15:30 14AP4 Poster Area - ROW 14B 213
03.06.2013 10:30-12:00 14AP5 Poster Area - ROW 8B 215
03.06.2013 12:15-13:45 14AP6 Poster Area - ROW 9B 217
03.06.2013 16:00-17:30 14AP7 Poster Area - ROW 13A 220
03.06.2013 16:00-17:30 14AP8 Poster Area - ROW 14A 223
Subcommittee 15 - Education, Research and Presentation
02.06.2013 08:30-10:00 15AP1 Poster Area - ROW 4A 226
03.06.2013 16:00-17:30 15AP2 Poster Area - ROW 15A 228
03.06.2013 16:00-17:30 15AP3 Poster Area - ROW 16A 230
Subcommittee 17 - Patient Safety
03.06.2013 12:15-13:45 17AP1 Poster Area - ROW 10B 233
04.06.2013 08:30-10:00 17AP2 Poster Area - ROW 7B 236
04.06.2013 08:30-10:00 17AP3 Poster Area - ROW 8B 239
04.06.2013 08:30-10:00 17AP4 Poster Area - ROW 10A 242
Subcommittee 18 - Perioperative Care of the Elderly
02.06.2013 10:30-12:00 18AP1 Poster Area - ROW 8A 244
03.06.2013 14:00-15:30 18AP2 Poster Area - ROW 19A 246
Subcommittee 19 - Airway Management
01.06.2013 15:00-16:30 19AP1 Poster Area - ROW 9B 249
02.06.2013 10:30-12:00 19AP2 Poster Area - ROW 9B 252
03.06.2013 10:30-12:00 19AP3 Poster Area - ROW 9A 255
03.06.2013 16:00-17:30 19AP4 Poster Area - ROW 17B 259
03.06.2013 16:00-17:30 19AP5 Poster Area - ROW 18B 262
04.06.2013 08:30-10:00 19AP6 Poster Area - ROW 11A 266
Subject Index
Author Index
271
277
The abstracts published in this Supplement have been typeset from electronic submissions and camera-ready copies prepared by the au-
thors. Every effort has been made to reproduce faithfully the abstracts as submitted. These abstracts have been prepared in accordance
with the requirements of the European Society of Anaesthesiology and have not been subjected to review nor editing by the European
Journal of Anaesthesiology. However, no responsibility is assumed by the organisers or publisher for any injury and/or damage to persons
or property as a matter of products liability, negligence or otherwise, or from any use or operation of methods, products, instructions or
ideas contained in the material herein. Because of the rapid advances in medical sciences, we recommend that independent verification of
diagnoses and drug doses should be made.

Call for abstracts
The ESA solicits the submission of abstracts for the
Euroanaesthesia 2014 Congress
Stockholm, Sweden
May 31 - June 3 2014
All abstracts must be submitted online via the ESA Website
www.euroanaesthesia.org
The submission module will be available to submitters
from November to December 2013
Submission Conditions
When submitting your abstract, you will be prompted to accept the
sub mission conditions that will be made available on the ESA website
at least one month before the submission starts.
ESA Best Abstract Prize Competition (BAPC) 1
ESA Best Abstract Prize Competition (BAPC)
ESAPC1-1
The neuroprotective effects of oxaloacetate and puruvate in
POV (RR 0.48 [0.31, 0.74]) and late POV (RR 0.50 [0.35, 0.73]; Figure 2).
a rat model of subarachnoid hemorrhage is mediated by its NCoo nrcelgurseisosniosn: asymmetry test results for the funnel plots were statistically
blood glutamate scavenging activity significant.
This meta-analysis excluding Fujii et al.’s RCTs suggests that
ramosetron has a significant effect in preventing PON and/or POV compared
Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion
BUoniyvkeors Mity., oGf rtuheen Nbeaguemv ,S D.Ee.p, aGrrtumeennbt aouf mAn Be.sF.t,h Desuiboilloegt yM a.,n Zdl oCtnritikic Aal. Care, with a placebo, but less than that reported in previous analyses.
Beer Sheva, Israel
Background and Goals of Study:
Subarachnoid hemorrhage (SAH) is as-
sociated with significant morbidity and mortality. Glutamate scavengers have
been shown to decrease glutamate concentrations in the blood and improve
neurological outcome following ischemic stroke and traumatic brain injury in
rats.
This study examines the value of blood glutamate scavengers, pyruvate and
oxaloacetate, as a therapeutic neuroprotective strategy in a rat model of SAH.
WMaet eardidailtsio annaldly Minevtehsotidgsa:t ed whether glutamate scavenging was the mecha-
nism responsible for any resulting neuroprotection.
SAH was induced in 60 rats by autologous arte-
rial blood injection into the cisterna magnum. 20 additional rats served as
the sham group, with a 0.3 ml saline injection into the cisterna magnum. 60
minutes later, rats were treated with isotonic saline, 250 mg/kg oxaloacetate,
or 125 mg/kg pyruvate by intravenous infusion for 30 minutes at a rate of 0.1
ml/100g/min. Prior to the induction of SAH (baseline) and 90 minutes after
SAH, blood samples were collected. Rats’ neurological status was measured
24 hours following SAH. Glutamate concentrations in the CSF of half of the [Figure 1]
rats were also measured 24 hours following SAH. The blood brain barrier
(RBeBsBu)l tps earmnde aDbiilsitcyu isns tihoen :p arieto-occipital and frontal lobes was assessed in
the remaining half via histological analysis 48 hours following SAH.
Blood glutamate levels were decreased in rats
treated with pyruvate or oxaloacetate at 90 minutes following SAH (p <
0.001). CSF glutamate was decreased in rats treated with pyruvate (p< 0.05).
Neurological performance improved significantly in rats treated with pyruvate
(p< 0.01) or oxaloacetate (p< 0.05). There was less BBB breakdown in the
pCaorniectlou-soicocnipsi:t al lobes in rats treated with oxaloacetate (p< 0.01) or pyruvate
(p< 0.01), and in the frontal lobe in rats treated with pyruvate (p< 0.05).
This study suggests the effectiveness of blood glutamate scav-
engers, pyruvate and oxaloacetate, in the treatment of SAH in rats. The data
sAucgkgneoswtsle thdagte tmhee onbtss:e rved neuroprotection with treatment of pyruvate or oxa-
loacetate is mediated via their blood glutamate scavenging effect.
This work was supported by the grant awarded to
Alexander Zlotnik MD, PhD from the European Society of Anesthesiologists
in 2010.
ESAPC1-2
Re-evaluation of the effectiveness of ramosetron in preventing
post-operative nausea and vomiting: a meta-analysis without
Fujii et al.’s RCTs
[Figure 2]
Yokohama City University School of Medicine, Dept of Anaesthesiology &
MIntiheanrsaiv Te. ,C Taorjoe ,K Y.o, kGoohtaom Ta., Japan
ESAPC1-3
Background:
Drug interaction models are better predictors of tolerance/
5-hydroxy-tryptamine receptor 3 antagonists (e.g. ramosetron) response to noxious stimuli compared to individual measured
are used to prevent post-operative nausea and vomiting (PONV). Ramosetron parameters
has been shown to have a very strong effect (Relative Risk = 0.3) in prevent-
ing PONV in previous meta-analyses. However, these previous meta-analyses
included a number of studies by Fujii et al. which have now been proven HUnainvneirvsoitoyr ot fL G.Nr.o, nPinrogoesnt, JU.Hni.v, eErsleitvye lMd eDd.Jic.,a Sl Ctreunytse Mr G.Mro.Rn.inF.,g Leung, iDnebpüth ol fM .,
to have been fabricated. We believe that the conclusion will change if ramo- VAenraeeescthkees Hio.lEo.gMy., Groningen, Netherlands
setron is re-evaluated without Fujii et al.’s studies. The aim of the present
mMeettah-oadnsa:ly sis was to re-evaluate the effectiveness of ramosetron in prevent- Background and Goal of Study:
ing PONV after excluding Fujii et al.’s randomized controlled trials (RCTs).
We searched MEDLINE, CENTRAL, Embase, and Web of Science. This study continues the pursuit of the pa-
All double-blind RCTs that tested the efficacy of ramosetron compared rameter with the best correlation to the probability of response to noxious
with a placebo in the prophylaxis of PONV were considered to be eligible. stimu1li of different intensity. We used data from a previous study by Heyse
Dichotomous data were summarized using risk ratio (RR) 2with a 95% confi- Met aatle.r ioanls thaen din Mteerathctoiodns :o f sevoflurane and remifentanil to compare several
dence interval (CI). Heterogeneity was quantified with the I statistic. parameters.
PRuebsluicltast:io n bias was assessed using a funnel plot and Egger’s regression After institutional review board approval, 40 adult
asymmetry test. patients were randomised to receive different combinations of sevoflurane
A total of 734 patients were included in the final analysis. In com- (Sevo) and remifentanil (Remi) according to a criss-cross design. After reach-
parison with a placebo, ramosetron reduces the incidence of early PON (RR ing pseudo-steady state, the patients were assessed for tolerance of ‘shake
[95%CI] 0.59 [0.47, 0.73]), late PON (RR 0.65 [0.49, 0.85]; Figure 1), early and shout’ (SAS), tetanic stimulation (TET), insertion of laryngeal mask airway
2 ESA Best Abstract Prize Competition (BAPC)
(LMA) and laryngoscopy (LAR). Bispectral index (BIS), state and response en- tRioenfe arnexniecteys,: eating disturbances and aggression against authority estimated
tropy (SE, RE), composite variability index (CVI) and surgical pleth index (SPI) by results of PHBQ.
were either recorded or computed from raw electroencephalographic and
plethysmographic data retrospectively. Sevo and Remi concentrations were 1. Kain ZN et al. Anesth Analg 2004;99:1648.
recorded. The combined potency of Sevo and Remi according to the fixed 2. Karling M et al. Acta Paediatr 2006;95:340.
C50O hierarchical interaction model (U) and the noxious stimulation response ESAPC1-5
index (NSRI) were the population-based predictors. We used the prediction Genetic factors contribute to enhanced fibrinolytic activity in
probability (PK) to assess the performance of these parameters on the prob- patients undergoing cardiac surgery
ability of response. Bootstrapping (n=1000) was used to produce 84%-confi-
Rdeenscuelt sin taenrvda lDs isocf uthses iPoKns:, with significance being achieved if the confidence
Pauls Stradins Clinical University Hospital, Dept of Anaesthesiology &
intervals did not overlap (p < 0.05).
The parameter PKs per stimulus are summarised OInzteonlisniave A C., aSrter,ik Rei gEa.,, JLaautvniaalksne I., Nikitina Zake L., Harlamovs V., Vanags I.
in Table 1. U NSRI Sevo Remi BIS SE RE CVI SPI
Background and Goal of Study:
SAS
TET 96% 96% 89% * 60% * 95% 93% 93% 92% 57% * Low plasma levels of plasminogen activator
LMA 96% 94% 79% * 69% * 84% * 84% * 84% * 83% * 53% * inhibitor -1 (PAI-1) and tissue plasminogen activator/PAI-1 (t-PA/PAI-1) complex
are associated with enhanced fibrinolysis. The Renin Angiotensin Aldosteron
LAR 98% 95% 81% * 63% * 83% * 81% * 81% * 79% * 57% * system (RAAS) regulates the fibrinolysis. Angiotensin IV and Aldosteron trig-
[Table 1. P9a8r%amete95r %pred7ic6t%io *n pr7o2b%a *bilit7ie8s%] * 78% * 77% * 74% * 58% * ger the generation of PAI-1 whereas Bradykinin stimulates secretion of t-PA.
Recent studies indicate that genetic factors determine the plasma levels of
PAI-1 and t-PA/PAI-1, influencing blood loss after surgery employing cardio-
* p < 0.05, compared to U and NSRI pulmonary bypass (CPB).
The goal: To investigate the potential effects of PAI-1 4G/5G and 844 A/G gene
The PK for U and NSRI were highest for all stimuli. Effect site concentrations of polymorphisms and Angiotensin converting enzyme (ACE) intron 16 I/D gene
either Sevo or Remi alone were significantly worse predictors. BIS, SE, RE and pMoelythmoodrsp:h ism on fibrinolytic activity in patients after cardiac surgery with
CCVoIn wcleursei osing:n ificantly worse at predicting tolerance to the three painful stimuli, CPB.
but similar to U and NSRI for SAS. SPI performed poorly overall. After ethical approval, 90 patients were studied prospectively,
U and NSRI perform significantly better than EEG-derived pa- whereof 7 were excluded because of surgical bleeding. In 83 patients, PAI-1
rameters and single drug effect site concentrations in predicting tolerance gene 4G/5G and 844 A/G, and ACE intron 16 I/D polymorphisms were ana-
tRoe nfeorxeionucse ss:ti muli. Therefore both U and NSRI could be useful parameters in lyzed. To asses fibrinolysis, PAI-1 and t-PA/PAI-1 complex were determined
anaesthetic practice. preoperatively and 24 h postoperatively, respectively, and D-dimer at 0 h, 6 h
and 24 h after surgery. Postoperative accumulated 24 h bleeding volume was
1. Heyse B, Proost JH, Schumacher PM, et al. Anesthesiology 2012;116:311-23. registered. Associations between 24 h blood loss, genetic polymorphisms,
ESAPC1-4
pRaersaumltest:e rs of fibrinolysis were analyzed separately for each polymorphism
Does total intravenous anesthesia decrease postoperative using SPSS 18.
behavioral changes after adenotonsillectomy in children? The following genotypes were detected: PAI-1 gene 4G/5G, 4G/4G,
5G/5G, PAI-1 844 A/A, A/G, G/G and ACE intron16 I/I, I/D, D/D genotypes. The
lowest PAI-1 levels preoperatively were associated with PAI-1 5G/5G (17±11
SUtnoivjaenrsoivtiyc H Sotisppicit aSl .S, pKlaitr,d Duemp tG o.f, ACnaareesv thMe.,s iRoolojeg yZ &., MInitleannsoivviec CLaitrree ,D S.,p lit, ng/ml), PAI-1 844 G/G (18±12 ng/ml) and ACE intro 16 I/I (18±11 ng/ml) gen-
EClreozaotivaic N. otype groups. The t-PA/PAI-1 complex reached the lowest level in the ACE
intron 16 I/I carriers (2.8±2 ng/ml).
24-hour blood loss differed significantly between PAI-1 4G/4G and 5G/5G
Background and Goal of Study:
(432±168 vs 568±192 ml; p=0.02), PAI-1 4G/4G and 4G/5G (432±168 vs
Postoperative behavioral changes (PBC) 609±321 ml; p=0.02) and PAI-1 844 G/G and A/A carriers (601±221 vs
occur in up to 50% of children undergoing surgery and general anesthesia. 436±266 ml; p=0.03). 24-hour blood loss in the ACE intron16 gene genotype
They include general anxiety, sleep disorders, enuresis and temper tantrums; groups did not differ significantly.
if PBC persist, the emotional and cognitive development may be significantly PAI-1 5G/5G carriers displayed the highest D-dimer levels at 6, 24 h after sur-
affected (1). Total intravenous anesthesia (TIVA) is increasingly used in routine gCeornyc alunsdi oPnAsI-:1 844 G/G carriers at 24 h. Within the ACE intron16 I/D groups,
pediatric anesthesia. The aim of this study was to assess whether the choice D-dimer did not differ significantly.
oMf adteifrfiearlesn at nadn eMseththetoicd ste: chniques for adenotonsillectomy may impact upon Enhanced fibrinolysis may be associated with PAI-1 gene
the incidence of PBC in repeated measurements. 5G/5G, 844 G/G and ACE Intron 16 I/I genotypes which can influence the
The children (n=36), age 6-12 yrs, were randomized blood loss.
ESAPC1-6
into 2 groups: TIVA (n=18) and sevoflurane (S) (n=18). After applying EMLA
cream, all patients had iv line before the induction and were given midazolam Safety of epidural and spinal regional anesthesia in
0.05 µg/kg. In TIVA group anesthesia was induced with propofol, fentanyl over 100,000 consecutive major lower extremity joint
and vecuronium,and maintained with continuous infusion of propofol. In S replacements - a case series
group, after fentanyl 1 µg/kg anesthesia was induced and maintained with
sevoflurane in O2/N20 (50:50) mixture. BIS monitoring was used and depth
of anesthesia accordingly adjusted. All patients were given paracetamol
PHuomspbitearlg foerr MSp.,e Mcieaml Stsuorguedrisy ,S W.Ge.il,l SMtuenddicnael rC Oo.l,l eHgeer zoof gC Ror.n, Belol eUtntniveerr sF.i,t y,
15 mg/kg and dexamethasone 0.2 mg/kg. PBC were evaluated with Post
HDeupgahretsm Ae.nP.ts of Anesthesiology and Orthopedic Surgery, New York, United
Hospitalization Behavior Questionnaire (PHBQ), consisting of 27 items de-
States
scribing 6 subscales: General Anxiety, Separation Anxiety, Sleep Anxiety,
Eating Disturbances, Aggression Against Authority and Apathy/Withdrawal
Background and Goal of Study:
(2). PHBQ was fulfilled by parents at days 1,3,7 and 15, as well as 6 months
aRfetesru lstus rgaenryd. TDheis cduastas iwoner: e statistically analyzed with repeated measures A feared complication of spinal or epidural
ANOVA.
anesthesia is the development of epi- or intradural hematomas with subse-
Regarding the Separation Anxiety, Eating
quent neural element compression. Most data available are derived form the
Disturbances and Aggression Against Authority subscales, there were sig-
obstetric literature. However, little is known on the frequency of its occurrence
nificant differences between TIVA and S group (P< 0.05) in all repeated
in the orthopedic joint arthroplasty population, which is usually elderly and
measurements, with greater mean values of PBC in S group. Regarding the
suffers from significant comorbid burden. We sought to study the incidence
General Anxiety, Sleep Anxiety and Apathy/Withdrawal subscales, there were
oMf actleinriicaalsll ya snigdn Mifiecathnot dless:i ons after spinal and epidural anesthesia and further
no significant differences either in repeated measurements within groups, or
describe their nature.
bCeotnwceluesni oTnIV:A and S group, although higher mean values of PBC were re- We analyzed charts of all patients who underwent
corded in group S (P>0.05).
THA or TKA under neuraxial anesthesia at our institution between January
The choice of anesthetic technique could affect PBC. Children
2000 and October 2010. Patients with radiographically confirmed epidural le-
anesthetized with TIVA for adenotonsillectomy had significantly less separa-
sions were identified and further analyzed.